Original Article
Misdiagnosis of Hereditary Amyloidosis as AL (Primary) Amyloidosis
N Engl J Med 2002; 346:1786-1791June 6, 2002
- Abstract
Background
Hereditary, autosomal dominant amyloidosis, caused by mutations in the genes encoding transthyretin, fibrinogen A α-chain, lysozyme, or apolipoprotein A-I, is thought to be extremely rare and is not routinely included in the differential diagnosis of systemic amyloidosis unless there is a family history.
Methods
We studied 350 patients with systemic amyloidosis, in whom a diagnosis of the light-chain (AL) type of the disorder had been suggested by clinical and laboratory findings and by the absence of a family history, to assess whether they had amyloidogenic mutations.
Results
Amyloidogenic mutations were present in 34 of the 350 patients (9.7 percent), most often in the genes encoding fibrinogen A α-chain (18 patients) and transthyretin (13 patients). In all 34 of these patients, the diagnosis of hereditary amyloidosis was confirmed by additional investigations. A low-grade monoclonal gammopathy was detected in 8 of the 34 patients (24 percent).
Conclusions
A genetic cause should be sought in all patients with amyloidosis that is not the reactive systemic amyloid A type and in whom confirmation of the AL type cannot be obtained.
Media in This Article
Figure 2
Renal-Biopsy Specimen from a Patient with the Glu526Val Variant of Fibrinogen A α-Chain Amyloidosis.Figure 1
Progression of Amyloid Deposits in a Patient with the Glu526Val Variant of Fibrinogen A α-Chain Amyloidosis and an Incidental Monoclonal Gammopathy.Article Activity
- Article
Systemic amyloidosis is the diagnosis in 2.5 percent of all native renal biopsies,1 and the cause of death in more than 1 in 1500 people in the United Kingdom annually. Acquired monoclonal immunoglobulin light-chain (AL) amyloidosis, formerly known as primary amyloidosis, is the most common form of systemic amyloidosis and can respond to chemotherapy directed at the underlying plasma-cell dyscrasia.2-5 Scintigraphy with labeled serum amyloid P component (SAP), a technique for quantitatively imaging amyloid deposits in vivo,6 has shown that deposits frequently regress after a reduction in monoclonal light-chain production.7 The chief consideration in the differential diagnosis of AL amyloidosis is reactive systemic amyloid A (AA) amyloidosis, but this form of the disorder is always a complication of chronic inflammation, and amyloid A deposits can usually be verified immunohistochemically.8 Another possibility is hereditary systemic amyloidosis, in which the amyloid fibrils are usually derived from genetic variants of transthyretin,9 apolipoprotein A-I,10,11 lysozyme,12 or fibrinogen A α-chain.13 However, these autosomal dominant conditions, which are thought to be extremely rare, are generally not considered in the differential diagnosis in patients without a relevant family history.
The diagnosis of hereditary amyloidosis has implications for prognosis, genetic counseling, and treatment, which may include liver transplantation to correct the underlying metabolic defect. Although most reported mutations causing hereditary amyloidosis show high penetrance, amyloidogenic mutations have occasionally been identified in asymptomatic elderly patients. In addition, population and haplotype studies have raised the possibility that two specific mutations associated with hereditary amyloidosis — one encoding the substitution of methionine for valine at position 30 of transthyretin (Val30Met) and one encoding the substitution of valine for glutamic acid at position 526 of fibrinogen A α-chain (Glu526Val) — may not be rare.14 We systematically studied patients with apparently sporadic systemic AL amyloidosis to determine whether any of the patients in fact had hereditary amyloidosis.
Methods
Patients
The genes for transthyretin, apolipoprotein A-I, lysozyme, and fibrinogen A α-chain were studied in all 350 patients referred to the National Amyloidosis Centre of the United Kingdom between 1997 and 2000 with biopsy-proved amyloidosis and a presumptive diagnosis of systemic AL amyloidosis. All the patients gave oral informed consent for the genetic analyses. None of them were aware of any illness in their family that was consistent with the presence of hereditary amyloidosis, and the amyloid in each case was shown by immunohistochemical analysis not to be the AA type. Serum and urine electrophoresis and immunofixation showed that 80 percent of the patients had a monoclonal gammopathy, a proportion similar to those in other series of patients with AL amyloidosis.15
In all the patients, clinical assessment included electrocardiography, Doppler echocardiography, and scintigraphy with 123I-labeled SAP, a method of imaging visceral amyloid deposits. Comprehensive immunohistochemical staining for amyloid fibril proteins was performed on amyloid-containing tissue from patients in whom potentially amyloidogenic mutations were identified. In addition, newly identified mutations in the genes for amyloid proteins were sought in 50 anonymous white controls from the general British population. Twenty-two clinically healthy first-degree relatives of patients with hereditary fibrinogen A α-chain Glu526Val amyloidosis were also studied.
Genotyping, Scintigraphy, and Immunohistochemistry
DNA was isolated as previously described from samples of whole blood treated with EDTA.11 The coding regions of the genes encoding transthyretin, apolipoprotein A-I, fibrinogen A α-chain (part of exon 5), and lysozyme (exon 2) were amplified by the polymerase-chain-reaction assay with the use of primers, solutions, and cycling conditions that have been described elsewhere.11,12,16,17 The products of the polymerase chain reaction were sequenced with the use of terminator reagent (ABI BigDye version 3.0, AB Applied Biosystems) according to the manufacturer's instructions.
Anterior and posterior whole-body scintigrams (Elscint Super Helix, GE Medical Systems) were obtained 24 hours after the intravenous injection of 200 MBq of 123I-labeled SAP.6 The scans were interpreted by a single physician with extensive experience.
Six-micrometer tissue sections were tested for the presence of amyloid by Congo-red staining and a search for pathognomonic red–green birefringence under cross-polarized light microscopy.18 Immunohistochemical staining was performed on 2-μm sections of amyloid-containing tissue with the use of commercial antiserum (Dako; Medix; and Helena Biosciences) against serum amyloid A protein, immunoglobulin κ and λ light chains, transthyretin, lysozyme, apolipoprotein A-I, and fibrinogen, as previously described.19 Positive control tissues containing each of these types of amyloid protein were also stained during each run.
Results
Of the 350 patients with systemic amyloidosis in this study, 18 (5.1 percent) were heterozygous for a point mutation that encoded the Glu526Val substitution in fibrinogen A α-chain. This mutation was not present in the 50 healthy controls. All 18 patients were of northern European ancestry, and none were aware of any relevant family history. However, genealogic studies performed after the genetic diagnosis revealed that two of the patients were cousins and that ancestors of two other patients had lived in adjacent villages. A fifth patient retrospectively ascertained that her dizygotic twin had died of renal failure at the age of 76 years. The other 13 patients had no such history and apparently were not related. The median age of the 18 patients at the time of presentation was 59 years; the youngest was in her 30s, and the oldest was 78 years old. At this writing, the latter patient remains well at the age of 81, despite impaired renal function. All 18 patients presented with isolated renal dysfunction and proteinuria, and most of them had moderate hypertension. Spontaneous splenic rupture occurred in two patients. Twelve patients became dependent on dialysis, with a median interval of 2.3 years between presentation and the development of renal failure. All nine of the patients who were followed up for more than five years eventually had end-stage renal failure.
The distribution of fibrinogen A α-chain amyloid revealed by 123I-labeled SAP scintigraphy was consistent. All 18 patients with the Glu526Val variant had renal deposits, and splenic amyloid was present in all but 1. Two patients, both of whom had initially presented with renal impairment more than a decade before their participation in this study, had hepatic amyloidosis. Amyloid deposits in bone, a pathognomonic feature of AL amyloidosis, were not identified in any of the patients. The electrocardiogram and echocardiogram did not suggest the presence of cardiac amyloidosis in any of the patients, and none had evidence of peripheral or autonomic neuropathy. In addition, none of the patients had clinical evidence of hemorrhagic or thrombotic tendencies, and the thrombin time, prothrombin time, activated partial-thromboplastin time, and fibrinogen levels were normal in all cases. Four of the 18 patients with a mutation in the gene encoding fibrinogen A α-chain also had low-grade paraproteinemia; in each case the level of paraprotein was less than 0.2 g per deciliter. The presence of these monoclonal gammopathies had reinforced the initial misdiagnosis of AL amyloidosis, and three of the four patients had received cytotoxic chemotherapy without a clinical response (Figure 1Figure 1
Progression of Amyloid Deposits in a Patient with the Glu526Val Variant of Fibrinogen A α-Chain Amyloidosis and an Incidental Monoclonal Gammopathy.).Twelve of the 22 first-degree relatives of patients with fibrinogen A α-chain amyloidosis were heterozygous for the mutation encoding the Glu526Val variant. All of them were more than 50 years old, and none had proteinuria or evidence of amyloidosis on 123I-labeled SAP scintigraphy.
Thirteen patients were heterozygous for point mutations in the gene encoding transthyretin (Table 1Table 1
Characteristics of 16 Patients with Hereditary Amyloidosis Due to a Mutation in the Gene Encoding Transthyretin, Lysozyme, or Apolipoprotein A-I.); three of these point mutations have apparently not been described previously: Phe33Val, Asp38Val, and Ala120Ser (GenBank accession numbers AF485254, AF485253, and AF485252, respectively). All 13 of these patients presented with cardiac amyloidosis and variable degrees of autonomic and peripheral neuropathy. In none of them did 123I-labeled SAP scintigraphy reveal any amyloid deposits in the liver or bone; such deposits have not been noted in transthyretin-associated amyloidosis. None of these 13 patients had any relevant family history.One patient who had presented with slowly progressive renal impairment was heterozygous for an amyloidogenic mutation encoding a lysozyme variant (in which histidine replaces aspartic acid at position 67 [Asp67His]), and another patient was heterozygous for a mutation encoding an apolipoprotein A-I variant (in which arginine replaces glycine at position 26 [Gly26Arg]). A man who had presented with hoarseness due to laryngeal amyloid and a long history of sterility with testicular amyloid on biopsy and in whom 123I-labeled SAP scintigraphy showed subclinical renal deposits of amyloid was found to be heterozygous for a novel mutation encoding an apolipoprotein A-I variant (in which proline replaces alanine at position 175 [Ala175Pro]) (GenBank accession number, AF485255).
Renal-biopsy specimens were available from 17 of the patients with the Glu526Val variant of fibrinogen A α-chain (Figure 2Figure 2
Renal-Biopsy Specimen from a Patient with the Glu526Val Variant of Fibrinogen A α-Chain Amyloidosis.). In all specimens, the amyloid deposits stained specifically with antifibrinogen antibodies, but there was marked variation in the intensity of the staining. There was staining for lysozyme and apolipoprotein A-I in specimens from the 3 patients who had mutations in the corresponding genes and staining for transthyretin in each of the 13 patients with a transthyretin variant. Robust, reproducible, immunospecific staining of amyloid deposits composed of these variant proteins required extensive preparation of the tissue specimens with the use of methods that included trypsin and microwave pretreatment.Intact monoclonal immunoglobulins were detected in the serum of 8 of the 34 patients with hereditary amyloidosis (24 percent), at levels of less than 0.2 g per deciliter, but in none of these patients were free light chains identified in the urine. By comparison, circulating paraproteins or urinary free light chains were present in 273 of the remaining 316 patients with AL amyloidosis (86 percent). However, there was no specific immunohistochemical staining of amyloid deposits with antibodies to κ or λ immunoglobulin light chains in any of the patients with hereditary amyloidosis or in 195 of the 316 patients with AL amyloidosis (62 percent).
Discussion
The identification of hereditary amyloidosis in almost 10 percent of patients with a presumptive diagnosis of systemic AL amyloidosis has several clinical implications. The single-gene mutations that cause hereditary amyloidosis evidently have variable penetrance, and most patients who have amyloidosis associated with the fibrinogen A α-chain Glu526Val variant — the most common form of hereditary amyloidosis identified in this study — do not have a relevant family history. Therefore, we now routinely perform DNA analysis in all patients with systemic amyloidosis. This practice has already prevented the inappropriate administration of chemotherapy to patients with a presumptive diagnosis of AL disease and has enabled potentially curative liver transplantations to be performed in four patients with previously unsuspected hereditary amyloidosis.
The clinical manifestations of the AL type of systemic amyloidosis are extremely heterogeneous. Macroglossia and periorbital ecchymoses are virtually pathognomonic, but they occur in only a minority of cases. Indeed, some of the characteristic patterns of organ involvement in AL amyloidosis are indistinguishable from those in familial amyloid polyneuropathy and hereditary non-neuropathic systemic amyloidosis. All patients with AL amyloidosis have an underlying clonal B-cell dyscrasia, but in only about 85 percent can a monoclonal protein be detected in the serum or urine. Because subtle monoclonal gammopathies are not infrequent in the general population,20 the detection of paraprotein in a patient with amyloidosis may be misleading, and thus it is essential to identify the actual amyloid fibril protein by immunohistochemical analysis whenever possible. Immunohistochemistry is usually definitive in identifying or ruling out AA amyloidosis, but it frequently is not diagnostic with respect to AL amyloidosis.8,21 In our series, AL fibrils were identified by immunohistochemical staining in only 121 of the 316 patients with confirmed AL disease (38 percent). This reflects the failure of anti–light-chain antibodies to bind to light-chain fragments with an abnormal cross-β amyloid-fibril conformation and also reflects background staining of normal immunoglobulins in the tissues. Specific fixation procedures or the use of unfixed, fresh-frozen tissue may yield better results, but ideally processed material is often not available after routine biopsies. Although the stored biopsy material we studied had not been uniformly processed, extensive use of optimization techniques allowed immunohistochemical confirmation of the DNA findings in each case.
The most common of the autosomal dominant systemic amyloidoses is caused by transthyretin variants. Patients usually present with familial amyloid polyneuropathy, with progressive peripheral and autonomic neuropathy; involvement of the heart or kidneys is variable. More than 80 amyloidogenic mutations in the gene encoding transthyretin have been identified,22 and we found 3 hitherto unreported variants. We also detected a transthyretin variant in which isoleucine replaces valine at position 122 (Val122Ile) in two patients, one of whom had amyloid neuropathy and cardiomyopathy. This variant occurs in 4 percent of black Americans,23 in whom it usually is silent or is associated with isolated late-onset cardiac amyloidosis. A transthyretin variant in which alanine replaces threonine at position 60 (Thr60Ala) is also associated with late-onset disease, reducing the likelihood of a relevant family history.
Patients with hereditary non-neuropathic systemic amyloidosis, which is caused by mutations in the genes encoding lysozyme,12 apolipoprotein A-I,10,11 or fibrinogen A α-chain,13 usually present with renal dysfunction. A mutation in the gene encoding apolipoprotein A-II24 has recently also been associated with hereditary renal amyloidosis. However, fewer than 30 families affected by any of these mutations have been described. The Glu526Val variant of the fibrinogen A α-chain25 has been reported in five families, all with clear cases of autosomal dominant amyloidosis. The present finding that the underlying mutation has low penetrance explains the previously enigmatic finding that haplotype studies in four of the families suggested that they had a common ancestor.26
The distinctive clinical picture of amyloidosis associated with the Glu526Val variant of fibrinogen A α-chain may reflect the tropism of this amyloid variant for the kidneys and its remarkable selectivity for glomeruli. All our patients presented with apparently isolated renal dysfunction, and in contrast to the usual progression of AL amyloidosis, the course of illness was prolonged and relatively benign. In most of the patients, renal dysfunction occurred after the age of 50 years, but in all of them end-stage renal failure associated with progressive accumulation of amyloid occurred within five years. The decline of renal function may have been exacerbated by hypertension in some of the patients, but no other risk factors for renal dysfunction were identified. In two of the patients, transplanted kidneys failed within six years because of severe amyloidosis in the graft. Only one patient had clinically significant extrarenal disease, in the form of liver failure, 15 years after her presentation. Another patient had subclinical deposition of amyloid in his liver 13 years after his kidneys had failed, and it is likely that the hepatic deposition was a late manifestation of this mutation. In this type of hereditary amyloidosis, unlike AL amyloidosis, cardiac involvement is not a feature.
In the patients with amyloidosis caused by the Asp67His variant of lysozyme and the Gly26Arg variant of apolipoprotein A-I, progressive renal impairment developed slowly, a phenotype similar to that in previously described kindreds.27,28 The patient with the Ala175Pro variant of apolipoprotein A-I, a newly identified variant, had hoarseness due to laryngeal amyloid deposits, a feature that commonly occurs in localized AL amyloidosis and that has also been reported in patients with mutations that disrupt this region of the apolipoprotein A-I molecule.29,30
AL amyloidosis often responds to chemotherapy that suppresses the underlying clonal plasma-cell disorder,2-5 but chemotherapy has no role in the treatment of hereditary amyloidosis and is dangerous. The types of hereditary amyloidosis in which the amyloidogenic protein is synthesized solely by the liver can be effectively treated by liver transplantation. This form of “surgical gene therapy”31 has been successful in familial amyloid polyneuropathy associated with variant forms of transthyretin and in amyloidosis due to the Glu526Val variant of fibrinogen A α-chain.17 However, the rate of progression of hereditary amyloidosis caused by variants of lysozyme, apolipoprotein A-I, and fibrinogen A α-chain is slow in many patients, in whom supportive measures and kidney transplantation alone are associated with an excellent outcome.
Supported in part by grants from the Medical Research Council, United Kingdom, and the Wellcome Trust (to Dr. Pepys and Dr. Hawkins); by a Wellcome Trust Research Training Fellowship (to Dr. Gillmore); and by National Health Service Research and Development Funds.
We are indebted to our many colleagues for referring and caring for the patients; to Sheril Madhoo, Dorothea Gopaul, and Jayshree Joshi for participating in the care and study of the patients at the National Amyloidosis Centre; and to Beth Jones for assistance in the preparation of the manuscript.
Source Information
From the National Amyloidosis Centre and Centre for Amyloidosis and Acute Phase Proteins, Department of Medicine, Royal Free and University College Medical School, Royal Free Campus, London.
Address reprint requests to Dr. Hawkins at the National Amyloidosis Centre, Department of Medicine, Royal Free and University College Medical School, Royal Free Campus, Rowland Hill St., London NW3 2PF, United Kingdom, or at p.n.hawkins@rfc.ucl.ac.uk.
- References
References
1
Davison AM . The United Kingdom Medical Research Council's glomerulonephritis registry. Contrib Nephrol 1985;48:24-35
Medline2
Gillmore JD ,Davies J ,Iqbal A ,Madhoo S ,Russell NH ,Hawkins PN . Allogeneic bone marrow transplantation for systemic AL amyloidosis. Br J Haematol 1998;100:226-228
CrossRef | Web of Science | Medline3
Kyle RA ,Gertz MA ,Greipp PR , et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997;336:1202-1207
Full Text | Web of Science | Medline4
Wardley AM ,Jayson GC ,Goldsmith DJ ,Venning MC ,Ackrill P ,Scarffe JH . The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone. Br J Cancer 1998;78:774-776
CrossRef | Web of Science | Medline5
Gertz MA ,Lacy MQ ,Dispenzieri A . Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report. Bone Marrow Transplant 2000;25:465-470
CrossRef | Web of Science | Medline6
Hawkins PN ,Lavender JP ,Pepys MB . Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med 1990;323:508-513
Full Text | Web of Science | Medline7
Hawkins PN . Studies with radiolabelled serum amyloid P component provide evidence for turnover and regression of amyloid deposits in vivo. Clin Sci (Lond) 1994;87:289-295
Web of Science | Medline8
Tan SY ,Pepys MB . Amyloidosis. Histopathology 1994;25:403-414
CrossRef | Web of Science | Medline9
Benson MD ,Uemichi T . Transthyretin amyloidosis. Amyloid 1996;3:44-56
CrossRef | Web of Science10
Nichols WC ,Dwulet FE ,Liepnieks J ,Benson MD . Variant apolipoprotein AI as a major constituent of a human hereditary amyloid. Biochem Biophys Res Commun 1988;156:762-768
CrossRef | Web of Science | Medline11
Soutar AK ,Hawkins PN ,Vigushin DM , et al. Apolipoprotein AI mutation Arg-60 causes autosomal dominant amyloidosis. Proc Natl Acad Sci U S A 1992;89:7389-7393
CrossRef | Web of Science | Medline12
Pepys MB ,Hawkins PN ,Booth DR , et al. Human lysozyme gene mutations cause hereditary systemic amyloidosis. Nature 1993;362:553-557
CrossRef | Web of Science | Medline13
Benson MD ,Liepnieks J ,Uemichi T ,Wheeler G ,Correa R . Hereditary renal amyloidosis associated with a mutant fibrinogen α-chain. Nat Genet 1993;3:252-255
CrossRef | Web of Science | Medline14
Holmgren G ,Costa PM ,Andersson C , et al. Geographical distribution of TTR met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate. J Med Genet 1994;31:351-354
CrossRef | Web of Science | Medline15
Kyle RA ,Gertz MA . Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45-59
Web of Science | Medline16
Booth DR ,Tan SY ,Hawkins PN ,Pepys MB ,Frustaci A . A novel variant of transthyretin, 59Thr-Lys, associated with autosomal dominant cardiac amyloidosis in an Italian family. Circulation 1995;91:962-967
Web of Science | Medline17
Gillmore JD ,Booth DR ,Rela M , et al. Curative hepatorenal transplantation in systemic amyloidosis caused by the Glu526Val fibrinogen α-chain variant in an English family. QJM 2000;93:269-275
CrossRef | Medline18
Puchtler H ,Sweat F ,Levine M . On the binding of Congo red by amyloid. J Histochem Cytochem 1962;10:355-364
CrossRef | Web of Science19
Tennent GA. Isolation and characterization of amyloid fibrils from tissue. In: Wetzel R, ed. Methods in enzymology. Vol. 309. Amyloid, prions, and other protein aggregates. San Diego, Calif.: Academic Press, 1999:26-47.
20
Kyle RA ,Therneau TM ,Rajkumar SV , et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002;346:564-569
Full Text | Web of Science | Medline21
Linke RP ,Gartner HV ,Michels H . High-sensitivity diagnosis of AA amyloidosis using Congo red and immunohistochemistry detects missed amyloid deposits. J Histochem Cytochem 1995;43:863-869
CrossRef | Web of Science | Medline22
Connors LH ,Richardson AM ,Theberge R ,Costello CE . Tabulation of transthyretin (TTR) variants as of 1/1/2000. Amyloid 2000;7:54-69
CrossRef | Web of Science | Medline23
Jacobson DR ,Pastore RD ,Yaghoubian R , et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med 1997;336:466-473
Full Text | Web of Science | Medline24
Benson MD ,Liepnieks JJ ,Yazaki M , et al. A new human hereditary amyloidosis: the result of a stop-codon mutation in the apolipoprotein AII gene. Genomics 2001;72:272-277
CrossRef | Web of Science | Medline25
Uemichi T ,Liepnieks JJ ,Benson MD . Hereditary renal amyloidosis with a novel variant fibrinogen. J Clin Invest 1994;93:731-736
CrossRef | Web of Science | Medline26
Uemichi T ,Liepnieks JJ ,Alexander F ,Benson MD . The molecular basis of renal amyloidosis in Irish-American and Polish-Canadian kindreds. QJM 1996;89:745-750
CrossRef | Medline27
Gillmore JD ,Booth DR ,Madhoo S ,Pepys MB ,Hawkins PN . Hereditary renal amyloidosis associated with variant lysozyme in a large English family. Nephrol Dial Transplant 1999;14:2639-2644
CrossRef | Web of Science | Medline28
Vigushin DM ,Gough J ,Allan D , et al. Familial nephropathic systemic amyloidosis caused by apolipoprotein AI variant Arg26. QJM 1994;87:149-154
Medline29
Hamidi Asl L ,Liepnieks JJ ,Hamidi Asl K , et al. Hereditary amyloid cardiomyopathy caused by a variant apolipoprotein AI. Am J Pathol 1999;154:221-227
CrossRef | Web of Science | Medline30
de Sousa MM ,Vital C ,Ostler D , et al. Apolipoprotein AI and transthyretin as components of amyloid fibrils in a kindred with apoAI Leul78His amyloidosis. Am J Pathol 2000;156:1911-1917
CrossRef | Web of Science | Medline31
Holmgren G ,Ericzon B-G ,Groth C-G , et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 1993;341:1113-1116
CrossRef | Web of Science | Medline
- Citing Articles (150)
Citing Articles
1
A.V. Kristen, C. Röcken. (2012) Amyloidose des Herzens. Der Pathologe
CrossRef2
Adam Castaño, Sabahat Bokhari, Thomas H. Brannagan, Julia Wynn, Mathew S. Maurer. (2011) Technetium pyrophosphate myocardial uptake and peripheral neuropathy in a rare variant of familial transthyretin (TTR) amyloidosis (Ser23Asn): a case report and literature review. Amyloid1-6
CrossRef3
Francesca Lavatelli, Julie A. Vrana. (2011) Proteomic typing of amyloid deposits in systemic amyloidoses. Amyloid 18:4, 177-182
CrossRef4
Violaine Planté-Bordeneuve, Gerard Said. (2011) Familial amyloid polyneuropathy. The Lancet Neurology 10:12, 1086-1097
CrossRef5
S. Schonland, U. Hegenbart, T. Bochtler, A. Mangatter, M. Hansberg, A. D. Ho, P. Lohse, C. Rocken. (2011) Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients. Blood
CrossRef6
Anjali A. Satoskar, Yvonne Efebera, Ayesha Hasan, Sergey Brodsky, Gyongyi Nadasdy, Ahmet Dogan, Tibor Nadasdy. (2011) Strong Transthyretin Immunostaining. The American Journal of Surgical Pathology 35:11, 1685-1690
CrossRef7
Prashant Kapoor, Thenappan Thenappan, Ekta Singh, Shaji Kumar, Philip R. Greipp. (2011) Cardiac Amyloidosis: A Practical Approach to Diagnosis and Management. The American Journal of Medicine 124:11, 1006-1015
CrossRef8
Stanley S. Levinson. (2011) Urine immunofixation electrophoresis remains important and is complementary to serum free light chain. Clinical Chemistry and Laboratory Medicine 49:11, 1801-1804
CrossRef9
Y. A. Rajabally. (2011) Neuropathy and paraproteins: review of a complex association. European Journal of Neurology 18:11, 1291-1298
CrossRef10
S. Schönland, N. Blank, A.V. Kristen, J. Beimler, T. Ganten, U. Hegenbart. (2011) Systemische Amyloidosen. Der Internist
CrossRef11
P. T. Sattianayagam, A. F. Hahn, C. J. Whelan, S. D. J. Gibbs, J. H. Pinney, D. Rowczenio, P. W. Pflugfelder, Z. Fox, H. J. Lachmann, A. D. Wechalekar, P. N. Hawkins, J. D. Gillmore. (2011) Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. European Heart Journal
CrossRef12
Dorota Rowczenio, Ahmet Dogan, Jason D. Theis, Julie A. Vrana, Helen J. Lachmann, Ashutosh D. Wechalekar, Janet A. Gilbertson, Toby Hunt, Simon D.J. Gibbs, Prayman T. Sattianayagam, Jenny H. Pinney, Philip N. Hawkins, Julian D. Gillmore. (2011) Amyloidogenicity and Clinical Phenotype Associated with Five Novel Mutations in Apolipoprotein A-I. The American Journal of Pathology 179:4, 1978-1987
CrossRef13
Ryuji Morizane, Toshiaki Monkawa, Konosuke Konishi, Akinori Hashiguchi, Mitsuharu Ueda, Yukio Ando, Hirobumi Tokuyama, Koichi Hayashi, Matsuhiko Hayashi, Hiroshi Itoh. (2011) Renal amyloidosis caused by apolipoprotein A-II without a genetic mutation in the coding sequence. Clinical and Experimental Nephrology 15:5, 774-779
CrossRef14
Prayman T. Sattianayagam, Simon D.J. Gibbs, Dorota Rowczenio, Jennifer H. Pinney, Ashutosh D. Wechalekar, Janet A. Gilbertson, Philip N. Hawkins, Helen J. Lachmann, Julian D. Gillmore. (2011) Hereditary Lysozyme Amyloidosis - Phenotypic Heterogeneity and the Role of Solid Organ Transplantation. Journal of Internal Medicineno-no
CrossRef15
Sanjeev Sethi, Jason D Theis, Shirley M Shiller, Cynthia C Nast, David Harrison, Helmut G Rennke, Julie A Vrana, Ahmet Dogan. (2011) Medullary amyloidosis associated with apolipoprotein A-IV deposition. Kidney International
CrossRef16
Pablo García-Pavía, María Teresa Tomé-Esteban, Claudio Rapezzi. (2011) Amiloidosis. También una enfermedad del corazón. Revista Española de Cardiología 64:9, 797-808
CrossRef17
Pablo García-Pavía, María Teresa Tomé-Esteban, Claudio Rapezzi. (2011) Amyloidosis. Also a Heart Disease. Revista Española de Cardiología (English Edition) 64:9, 797-808
CrossRef18
Albert Y. Wu, William B. Chapman, Ian J. Witterick, Dan D. DeAngelis. (2011) Bifocal Orbital and Nasopharyngeal Amyloidomas Presenting as Graves Disease. Ophthalmic Plastic & Reconstructive Surgery 27:5, e132-e134
CrossRef19
Yelda Bilginer, Tekin Akpolat, Seza Ozen. (2011) Renal amyloidosis in children. Pediatric Nephrology 26:8, 1215-1227
CrossRef20
Pablo García-Pavía, Patricia Avellana, Belén Bornstein, Damián Heine-Suñer, Marta Cobo-Marcos, Manuel Gómez-Bueno, Javier Segovia, Luis A. Alonso-Pulpón. (2011) Familial Approach in Hereditary Transthyretin Cardiac Amyloidosis. Revista Española de Cardiología (English Edition) 64:6, 523-526
CrossRef21
Manuel Cappellari, Tiziana Cavallaro, Moreno Ferrarini, Ilaria Cabrini, Federica Taioli, Sergio Ferrari, Giampaolo Merlini, Laura Obici, Chiara Briani, Gian Maria Fabrizi. (2011) Variable presentations of TTR-related familial amyloid polyneuropathy in seventeen patients. Journal of the Peripheral Nervous System 16:2, 119-129
CrossRef22
I. Tavares, L. Lobato, L. Moreira, J. Santos, P. Lacerda, J. Pinheiro, P. Costa. (2011) Long-term follow-up of patients with hereditary fibrinogen A alpha-chain amyloidosis. Amyloid 18:Suppl. 1, 221-222
CrossRef23
(2011) Abstracts. Amyloid 18:Suppl. 1, 6-238
CrossRef24
A. Foli, G. Palladini, R. Caporali, L. Verga, P. Morbini, L. Obici, P. Russo, G. Sarais, S. Donadei, C. Montecucco, G. Merlini. (2011) The role of minor salivary gland biopsy in the diagnosis of systemic amyloidosis: results of a prospective study in 62 patients. Amyloid 18:Suppl. 1, 80-82
CrossRef25
Andrew J. Cowan, Martha Skinner, John L. Berk, John Mark Sloan, Carl O'hara, David C. Seldin, Vaishali Sanchorawala. (2011) Macroglossia – not always AL amyloidosis. Amyloid 18:2, 83-86
CrossRef26
J. Rojas-Rivera, A. Barat, J. Egido. (2011) Glomerulopatías secundarias a enfermedades sistémicas. Medicine - Programa de Formación Médica Continuada Acreditado 10:82, 5560-5580
CrossRef27
Pablo García-Pavía, Patricia Avellana, Belén Bornstein, Damián Heine-Suñer, Marta Cobo-Marcos, Manuel Gómez-Bueno, Javier Segovia, Luis A. Alonso-Pulpón. (2011) Abordaje familiar en la amiloidosis cardiaca hereditaria por transtiretina. Revista Española de Cardiología 64:6, 523-526
CrossRef28
Jean-Michel Vallat, Benoît Funalot, Laurent Magy. (2011) Nerve biopsy: requirements for diagnosis and clinical value. Acta Neuropathologica 121:3, 313-326
CrossRef29
Claudio Rapezzi, Candida Cristina Quarta, Pier Luigi Guidalotti, Simone Longhi, Cinzia Pettinato, Ornella Leone, Alessandra Ferlini, Fabrizio Salvi, Pamela Gallo, Christian Gagliardi, Angelo Branzi. (2011) Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. European Journal of Nuclear Medicine and Molecular Imaging 38:3, 470-478
CrossRef30
Therése Klingstedt, K. Peter R. Nilsson. (2011) Conjugated polymers for enhanced bioimaging. Biochimica et Biophysica Acta (BBA) - General Subjects 1810:3, 286-296
CrossRef31
MUHAMMED MUBARAK, JAVED I KAZI, RUBINA NAQVI, EJAZ AHMED, FAZAL AKHTER, SYED AA NAQVI, SYED AH RIZVI. (2011) Pattern of renal diseases observed in native renal biopsies in adults in a single centre in Pakistan. Nephrology 16:1, 87-92
CrossRef32
Dorothy Loo, Peter N. Mollee, Patricia Renaut, Michelle M. Hill. (2011) Proteomics in Molecular Diagnosis: Typing of Amyloidosis. Journal of Biomedicine and Biotechnology 2011, 1-9
CrossRef33
Michael Rosenzweig, Heather Landau. (2011) Light chain (AL) amyloidosis: update on diagnosis and management. Journal of Hematology & Oncology 4:1, 47
CrossRef34
D. Adams, P. Lozeron, M. Théaudin, C. Adam, C. Lacroix. (2011) Neuropatie periferiche nel corso delle disglobulinemie. EMC - Neurologia 11:4, 1-14
CrossRef35
Charles L. Murphy, Shuching Wang, Daniel Kestler, Christopher Larsen, Don Benson, Deborah T. Weiss, Alan Solomon. (2010) Leukocyte Chemotactic Factor 2 (LECT2)-Associated Renal Amyloidosis: A Case Series. American Journal of Kidney Diseases 56:6, 1100-1107
CrossRef36
A. D. Cohen, R. L. Comenzo. (2010) Systemic Light-Chain Amyloidosis: Advances in Diagnosis, Prognosis, and Therapy. Hematology 2010:1, 287-294
CrossRef37
Pierre Ronco, Emmanuelle Plaisier, Pierre Aucouturier. (2010) Ig-Related Renal Disease in Lymphoplasmacytic Disorders: An Update. Seminars in Nephrology 30:6, 557-569
CrossRef38
Simon DJ Gibbs, Philip N Hawkins. 2010. Amyloidosis. , 599-613.
CrossRef39
P. T. Sattianayagam, S. D. J. Gibbs, J. H. Pinney, A. D. Wechalekar, H. J. Lachmann, C. J. Whelan, J. A. Gilbertson, P. N. Hawkins, J. D. Gillmore. (2010) Solid Organ Transplantation in AL Amyloidosis. American Journal of Transplantation 10:9, 2124-2131
CrossRef40
Shari Ghanny, Catherine Ross, Anthony K.C. Chan, Howard H.W. Chan. (2010) Coagulopathy in a patient with nephrotic syndrome. American Journal of Hematology 85:9, 708-710
CrossRef41
Claudio Rapezzi, Candida Cristina Quarta, Letizia Riva, Simone Longhi, Ilaria Gallelli, Massimiliano Lorenzini, Paolo Ciliberti, Elena Biagini, Fabrizio Salvi, Angelo Branzi. (2010) Transthyretin-related amyloidoses and the heart: a clinical overview. Nature Reviews Cardiology 7:7, 398-408
CrossRef42
Federico Perfetto, Alberto Moggi-Pignone, Riccardo Livi, Alessio Tempestini, Franco Bergesio, Marco Matucci-Cerinic. (2010) Systemic amyloidosis: a challenge for the rheumatologist. Nature Reviews Rheumatology 6:7, 417-429
CrossRef43
Steven R. Zeldenrust, Merrill D. Benson. 2010. Familial and Senile Amyloidosis Caused by Transthyretin. , 795-815.
CrossRef44
Angela Dispenzieri, Shaji Kumar. 2010. Current Therapies for Light-Chain Amyloidosis. , 775-793.
CrossRef45
Morie A. Gertz. 2010. Diagnosis of Systemic Amyloid Diseases. , 673-688.
CrossRef46
Cheng E. Chee, Martha Q. Lacy, Ahmet Dogan, Steven R. Zeldenrust, Morie A. Gertz. (2010) Pitfalls in the Diagnosis of Primary Amyloidosis. Clinical Lymphoma, Myeloma & Leukemia 10:3, 177-180
CrossRef47
Christopher P Larsen, Patrick D Walker, Deborah T Weiss, Alan Solomon. (2010) Prevalence and morphology of leukocyte chemotactic factor 2-associated amyloid in renal biopsies. Kidney International 77:9, 816-819
CrossRef48
A. J. Stangou, N. R. Banner, B. M. Hendry, M. Rela, B. Portmann, J. Wendon, M. Monaghan, P. MacCarthy, M. Buxton-Thomas, C. J. Mathias, J. J. Liepnieks, J. O'Grady, N. D. Heaton, M. D. Benson. (2010) Hereditary fibrinogen A -chain amyloidosis: phenotypic characterization of a systemic disease and the role of liver transplantation. Blood 115:15, 2998-3007
CrossRef49
Tom Pettersson, Yrjö T. Konttinen. (2010) Amyloidosis—Recent Developments. Seminars in Arthritis and Rheumatism 39:5, 356-368
CrossRef50
ZHEN QU, XIN ZHENG, SU-XIA WANG, JIE AO, FU-DE ZHOU, MIN CHEN, GANG LIU. (2010) Clinical and pathological features of renal amyloidosis: An analysis of 32 patients in a single Chinese centre. Nephrology 15:1, 102-107
CrossRef51
(2010) Renal biopsy is a relatively safe procedure in cases of suspected amyloidosis and a valuable tool in excluding non-AL forms of the disease. Internal Medicine Journal 40:2, 167-168
CrossRef52
K. Peter R. Nilsson, Kristian Ikenberg, Andreas Åslund, Sophia Fransson, Peter Konradsson, Christoph Röcken, Holger Moch, Adriano Aguzzi. (2010) Structural Typing of Systemic Amyloidoses by Luminescent-Conjugated Polymer Spectroscopy. The American Journal of Pathology 176:2, 563-574
CrossRef53
Nagaaki Katoh, Masayuki Matsuda, Takuhiro Yoshida, Masahide Yazaki, Hiroshi Morita, Kazuo Sakashita, Shu-Ichi Ikeda. (2010) Primary AL amyloid polyneuropathy successfully treated with high-dose melphalan followed by autologous stem cell transplantation. Muscle & Nerve 41:1, 138-143
CrossRef54
Harit V. Desai, Wilbert S. Aronow, Stephen J. Peterson, William H. Frishman. (2010) Cardiac Amyloidosis. Cardiology in Review 18:1, 1-11
CrossRef55
Toshiyuki Yamada. (2010) Laboratory test for amyloidosis. SEIBUTSU BUTSURI KAGAKU 54:1, 27-29
CrossRef56
Prayman Sattianayagam, Philip Hawkins, Julian Gillmore. (2009) Amyloid and the GI tract. Expert Review of Gastroenterology & Hepatology 3:6, 615-630
CrossRef57
P. Westermark. (2009) Amyloidose-Zentren in Europa. Der Pathologe 30:S2, 124-127
CrossRef58
G. T. Westermark, K. Sletten, P. Westermark. (2009) Alkali-Degradation of Amyloid: An Ancient Method Useful for Making Monoclonal Antibodies Against Amyloid Fibril Proteins. Scandinavian Journal of Immunology 70:6, 535-540
CrossRef59
C. Röcken. (2009) Update – Immunhistologische Klassifikation der Amyloidosen. Der Pathologe 30:S2, 121-123
CrossRef60
R. L. Comenzo. (2009) How I treat amyloidosis. Blood 114:15, 3147-3157
CrossRef61
(2009) Outcomes of Heart Transplantation for Cardiac Amyloidosis: Subanalysis of the Spanish Registry for Heart Transplantation. American Journal of Transplantation 9:10, 2443-2443
CrossRef62
Lawreen H. Connors, Tatiana Prokaeva, Amareth Lim, Roger Théberge, Rodney H. Falk, Gheorghe Doros, Alan Berg, Catherine E. Costello, Carl O'Hara, David C. Seldin, Martha Skinner. (2009) Cardiac amyloidosis in African Americans: Comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. American Heart Journal 158:4, 607-614
CrossRef63
Prayman T. Sattianayagam, Philip N. Hawkins, Julian D. Gillmore. (2009) Systemic amyloidosis and the gastrointestinal tract. Nature Reviews Gastroenterology & Hepatology 6:10, 608-617
CrossRef64
Karim Aissi, Pascal Rossi, Fanny Bernard, Brigitte Granel, Yves Frances. (2009) Facial Signs Leading to the Diagnosis of Cardiac Amyloidosis. The American Journal of Medicine 122:9, e1-e2
CrossRef65
Hanna von Hutten, Michael Mihatsch, Hartmut Lobeck, Birgit Rudolph, Magdalena Eriksson, Christoph Röcken. (2009) Prevalence and Origin of Amyloid in Kidney Biopsies. The American Journal of Surgical Pathology 33:8, 1198-1205
CrossRef66
K. Peter R. Nilsson. (2009) Small organic probes as amyloid specific ligands – Past and recent molecular scaffolds. FEBS Letters 583:16, 2593-2599
CrossRef67
Jean-Michel Vallat, Anne Vital, Laurent Magy, Marie-Laure Martin-Negrier, Claude Vital. (2009) An Update on Nerve Biopsy. Journal of Neuropathology & Experimental Neurology 68:8, 833-844
CrossRef68
A. Bernard Collins, R. Neal Smith, James R. Stone. (2009) Classification of amyloid deposits in diagnostic cardiac specimens by immunofluorescence. Cardiovascular Pathology 18:4, 205-216
CrossRef69
Magdalena Eriksson, Stefan Schönland, Saniye Yumlu, Ute Hegenbart, Hanna von Hutten, Zarina Gioeva, Peter Lohse, Janine Büttner, Hartmut Schmidt, Christoph Röcken. (2009) Hereditary Apolipoprotein AI-Associated Amyloidosis in Surgical Pathology Specimens. The Journal of Molecular Diagnostics 11:3, 257-262
CrossRef70
C. Röcken, M. Eriksson. (2009) Amyloid und Amyloidosen. Der Pathologe 30:3, 182-192
CrossRef71
Z. Gioeva, B. Kieninger, C. Röcken. (2009) Amyloidose in Leberbiopsien. Der Pathologe 30:3, 240-245
CrossRef72
S.O. Schönland, T. Bochtler, A.V. Kristen, A.D. Ho, U. Hegenbart. (2009) Aktuelle Diagnostik und Therapie der Leichtkettenamyloidose. Der Pathologe 30:3, 205-211
CrossRef73
Ingrid I van Gameren, Edo Vellenga, Bouke PC Hazenberg. (2009) Novel treatments for systemic amyloidosis. International Journal of Clinical Rheumatology 4:2, 171-188
CrossRef74
BoGun Jang, Youngil Koh, Jeong-Wook Seo. (2009) Immunohistochemical classification of amyloid deposits in surgical pathology. Basic and Applied Pathology 2:1, 1-8
CrossRef75
Merrill D. Benson, Jeffrey Breall, Oscar W. Cummings, Juris J. Liepnieks. (2009) Biochemical characterisation of amyloid by endomyocardial biopsy. Amyloid 16:1, 9-14
CrossRef76
Ashutosh D Wechalekar, Mark Offer, Julian D Gillmore, Philip N Hawkins, Helen J Lachmann. (2008) Cardiac amyloidosis, a monoclonal gammopathy and a potentially misleading mutation. Nature Clinical Practice Cardiovascular Medicine 6:2, 128-133
CrossRef77
Sandra M. Soares, Fernando C. Fervenza, Donna J. Lager, Morie A. Gertz, Fernando G. Cosio, Nelson Leung. (2008) Bleeding Complications After Transcutaneous Kidney Biopsy in Patients With Systemic Amyloidosis: Single-Center Experience in 101 Patients. American Journal of Kidney Diseases 52:6, 1079-1083
CrossRef78
A. D. Wechalekar, H. J. Lachmann, H. J. B. Goodman, A. Bradwell, P. N. Hawkins, J. D. Gillmore. (2008) AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome. Blood 112:10, 4009-4016
CrossRef79
G. Gahide, F. Roubille, J.C. Macia, V. Garrigue, H. Vernhet. (2008) Myocardial involvement in fibrinogen A–alpha chain amyloidosis. European Journal of Internal Medicine 19:7, e54-e56
CrossRef80
Morie A Gertz. (2008) Amyloidosis: diagnosis and prognosis. Future Rheumatology 3:4, 369-380
CrossRef81
Merrill D Benson. 2008. Amyloidosis. .
CrossRef82
Magdalena Eriksson, Stefan Schönland, Raoul Bergner, Ute Hegenbart, Peter Lohse, Hartmut Schmidt, Christoph Röcken. (2008) Three German fibrinogen Aα-chain amyloidosis patients with the p.Glu526Val mutation. Virchows Archiv 453:1, 25-31
CrossRef83
C. Röcken. (2008) Pathologie der Amyloidosen. Der Nephrologe 3:4, 275-284
CrossRef84
Benjamin Terrier, Arnaud Jaccard, Jean-Luc Harousseau, Richard Delarue, Olivier Tournilhac, Mathilde Hunault-Berger, Mohamed Hamidou, Jacques Dantal, Marc Bernard, Bernard Grosbois, Pierre Morel, Valérie Coiteux, Olivier Gisserot, Philippe Rodon, Arnaud Hot, Caroline Elie, Véronique Leblond, Jean-Paul Fermand, Fadi Fakhouri. (2008) The Clinical Spectrum of IgM-Related Amyloidosis. Medicine 87:2, 99-109
CrossRef85
G. Rojo Marcos, L. Bragado Martínez, F.J. García Segovia, M. Velo Plaza. (2008) Amiloidosis cardíaca primaria en un paciente con hipertensión arterial sistémica y miocardiopatía hipertensiva. Revista Clínica Española 208:1, 61-62
CrossRef86
J. Malcolm O. Arnold, Jonathan G. Howlett, Anique Ducharme, Justin A. Ezekowitz, Martin J. Gardner, Nadia Giannetti, Haissam Haddad, George A. Heckman, Debra Isaac, Philip Jong, Peter Liu, Elizabeth Mann, Robert S. McKelvie, Gordon W. Moe, Anna M. Svendsen, Ross T. Tsuyuki, Kelly O’Halloran, Heather J. Ross, Errol J. Sequeira, Michel White. (2008) Canadian Cardiovascular Society Consensus Conference guidelines on heart failure – 2008 update: Best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathies. Canadian Journal of Cardiology 24:1, 21-40
CrossRef87
Claudio Rapezzi, Letizia Riva, Cristina C. Quarta, Enrica Perugini, Fabrizio Salvi, Simone Longhi, Paolo Ciliberti, Francesca Pastorelli, Elena Biagini, Ornella Leone, Robin M. T. Cooke, Letizia Bacchi-Reggiani, Alessandra Ferlini, Michele Cavo, Giampaolo Merlini, Stefano Perlini, Sonia Pasquali, Angelo Branzi. (2008) Gender-related risk of myocardial involvement in systemic amyloidosis. Amyloid 15:1, 40-48
CrossRef88
Angela Dispenzieri, Giampaolo Merlini, Raymond L. Comenzo. (2008) Amyloidosis: 2008 BMT Tandem Meetings (February 13-17, San Diego). Biology of Blood and Marrow Transplantation 14:1, 6-11
CrossRef89
Joseph B. Selvanayagam, Philip N. Hawkins, Biju Paul, Saul G. Myerson, Stefan Neubauer. (2007) Evaluation and Management of the Cardiac Amyloidosis. Journal of the American College of Cardiology 50:22, 2101-2110
CrossRef90
Adam D. Cohen, Ping Zhou, Joanne Chou, Julie Teruya-Feldstein, Lilian Reich, Hani Hassoun, Beth Levine, Daniel A. Filippa, Elyn Riedel, Tarun Kewalramani, Michael D. Stubblefield, Martin Fleisher, Stephen Nimer, Raymond L. Comenzo. (2007) Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone
thalidomide for systemic light-chain amyloidosis: results of a phase II trial. British Journal of Haematology 139:2, 224-233
CrossRef91
S. Augustin, D. Llige, A. Andreu, A. González, J. Genescà. (2007) Familial amyloidosis in a large Spanish kindred resulting from a D38V mutation in the transthyretin gene. European Journal of Clinical Investigation 37:8, 673-678
CrossRef92
A.V. Kristen, E. Giannitsis, A. Bauer, S. Hardt, P.A. Schnabel, F.-U. Sack, H.A. Katus, T.J. Dengler. (2007) Kardiale Amyloidose. Der Kardiologe 1:2, 123-138
CrossRef93
K. L. Morris, J. R. Tate, D. Gill, G. Kennedy, J. Wellwood, P. Marlton, R. Bird, A. K. Mills, P. Mollee. (2007) Diagnostic and prognostic utility of the serum free light chain assay in patients with AL amyloidosis. Internal Medicine Journal 37:7, 456-463
CrossRef94
Lachmann, Helen J., Goodman, Hugh J.B., Gilbertson, Janet A.Gallimore, J. Ruth, Sabin, Caroline A., Gillmore, Julian D., Hawkins, Philip N., . (2007) Natural History and Outcome in Systemic AA Amyloidosis. New England Journal of Medicine 356:23, 2361-2371
Full Text95
Brian Garibaldi, David Zaas. (2007) An Unusual Case of Cardiac Amyloidosis. Journal of General Internal Medicine 22:7, 1047-1052
CrossRef96
Maria M Picken. (2007) New insights into systemic amyloidosis: the importance of diagnosis of specific type. Current Opinion in Nephrology and Hypertension 16:3, 196-203
CrossRef97
G. Grateau, S. Valleix, P. Callard. (2007) Les amyloses multisystémiques en 2007. La Revue de Médecine Interne 28:5, 281-283
CrossRef98
Batia Kaplan, Yael Shinar, Chen Avisar, Avi Livneh. (2007) Transthyretin amyloidosis in a patient of Iranian-Jewish extraction: a second Israeli-Jewish case. Clinical Chemistry and Laboratory Medicine 45:5, 625-628
CrossRef99
R P Hasserjian, H J B Goodman, H J Lachmann, A Muzikansky, P N Hawkins. (2007) Bone marrow findings correlate with clinical outcome in systemic AL amyloidosis patients. Histopathology 50:5, 567-573
CrossRef100
Morie A Gertz, Martha Q Lacy, Angela Dispenzieri, Suzanne R Hayman, Shaji Kumar. (2007) Transplantation for amyloidosis. Current Opinion in Oncology 19:2, 136-141
CrossRef101
Roy Freeman. (2007) Autonomic Peripheral Neuropathy. Neurologic Clinics 25:1, 277-301
CrossRef102
Eapen K. Jacob, William D. Edwards, Mark Zucker, Cyril D'Cruz, Surya V. Seshan, Frank W. Crow, W. Edward Highsmith. (2007) Homozygous Transthyretin Mutation in an African American Male. The Journal of Molecular Diagnostics 9:1, 127-131
CrossRef103
Hugh J. B. Goodman, Julian D. Gillmore, Helen J. Lachmann, Ashutosh D. Wechalekar, Arthur R. Bradwell, Philip N. Hawkins. (2006) Outcome of autologous stem cell transplantation for AL amyloidosis in the UK. British Journal of Haematology 134:4, 417-425
CrossRef104
Anja Kebbel, Christoph R??cken. (2006) Immunohistochemical Classification of Amyloid in Surgical Pathology Revisited. The American Journal of Surgical Pathology 30:6, 673-683
CrossRef105
Hugh J. B. Goodman, Philip N. Hawkins. (2006) Amyloidosis and Primary Biliary Cirrhosis, Rodriguez-Luna Et Al.. Digestive Diseases and Sciences 51:6, 1133-1133
CrossRef106
Raymond L. Comenzo. (2006) Amyloidosis. Current Treatment Options in Oncology 7:3, 225-236
CrossRef107
C. Mousson, B. Heyd, E. Justrabo, J.-M. Rebibou, Y. Tanter, J.-P. Miguet, G. Rifle. (2006) Successful Hepatorenal Transplantation in Hereditary Amyloidosis Caused by a Frame-Shift Mutation in Fibrinogen Aalpha-Chain Gene. American Journal of Transplantation 6:3, 632-635
CrossRef108
Mark B. Pepys. (2006) Amyloidosis. Annual Review of Medicine 57:1, 223-241
CrossRef109
Brigitte Granel, Sophie Valleix, Jacques Serratrice, Patrick Ch??rin, Antonio Texeira, Patrick Disdier, Pierre-Jean Weiller, Gilles Grateau. (2006) Lysozyme Amyloidosis. Medicine 85:1, 66-73
CrossRef110
Laura Obici, Guido Franceschini, Laura Calabresi, Sofia Giorgetti, Monica Stoppini, Giampaolo Merlini, Vittorio Bellotti. (2006) Structure, function and amyloidogenic propensity of apolipoprotein A-I. Amyloid 13:4, 191-205
CrossRef111
Morie A. Gertz, Martha Q. Lacy, Angela Dispenzieri, Suzanne R. Hayman. (2005) Amyloidosis. Best Practice & Research Clinical Haematology 18:4, 709-727
CrossRef112
Laura Obici, Vittorio Perfetti, Giovanni Palladini, Remigio Moratti, Giampaolo Merlini. (2005) Clinical aspects of systemic amyloid diseases. Biochimica et Biophysica Acta (BBA) - Proteins & Proteomics 1753:1, 11-22
CrossRef113
HEE GYUNG KANG, ALISON BYBEE, IL SOO HA, MOON SOO PARK, JANET A GILBERTSON, HAE IL CHEONG, YONG CHOI, PHILIP N HAWKINS. (2005) Hereditary amyloidosis in early childhood associated with a novel insertion-deletion (indel) in the fibrinogen Aα chain gene. Kidney International 68:5, 1994-1998
CrossRef114
L Q M Chow, N Bahlis, J Russell, A Chaudhry, D Morris, C Brown, D A Stewart. (2005) Autologous transplantation for primary systemic AL amyloidosis is feasible outside a major amyloidosis referral centre: the Calgary BMT Program experience. Bone Marrow Transplantation 36:7, 591-596
CrossRef115
Enrica Perugini, Pier Luigi Guidalotti, Fabrizio Salvi, Robin M.T. Cooke, Cinzia Pettinato, Letizia Riva, Ornella Leone, Mohsen Farsad, Paolo Ciliberti, Letizia Bacchi-Reggiani, Francesco Fallani, Angelo Branzi, Claudio Rapezzi. (2005) Noninvasive Etiologic Diagnosis of Cardiac Amyloidosis Using 99mTc-3,3-Diphosphono-1,2-Propanodicarboxylic Acid Scintigraphy. Journal of the American College of Cardiology 46:6, 1076-1084
CrossRef116
Morie A. Gertz, Ray Comenzo, Rodney H. Falk, Jean Paul Fermand, Bouke P. Hazenberg, Philip N. Hawkins, Giampaolo Merlini, Philippe Moreau, Pierre Ronco, Vaishali Sanchorawala, Orhan Sezer, Alan Solomon, Giles Grateau. (2005) Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. American Journal of Hematology 79:4, 319-328
CrossRef117
D. Launay, M.-C. Copin, E. Hachulla, M. Lambert, T. Quémeneur, S. Morell, V. Queyrel, B. Devulder, P.-Y. Hatron. (2005) Une amylose qui déclone. La Revue de Médecine Interne 26, S294-S295
CrossRef118
C. Ensari. (2005) Clinicopathological and epidemiological analysis of amyloidosis in Turkish patients. Nephrology Dialysis Transplantation 20:8, 1721-1725
CrossRef119
Paul W Sanders. (2005) Management of paraproteinemic renal disease. Current Opinion in Internal Medicine 4:3, 267-273
CrossRef120
Cabot, Richard C.Harris, Nancy Lee, Shepard, Jo-Anne O., Ebeling, Sally H.Ellender, Stacey M.Peters, Christine C., Dember, Laura M., Shepard, Jo-Anne O., Nesta, Francesca, Stone, James R., . (2005) Case 15-2005. New England Journal of Medicine 352:20, 2111-2119
Full Text121
Paul W Sanders. (2005) Management of paraproteinemic renal disease. Current Opinion in Nephrology and Hypertension 14:2, 97-103
CrossRef122
Merrill D Benson. (2005) Ostertag revisited: The inherited systemic amyloidoses without neuropathy. Amyloid 12:2, 75-87
CrossRef123
Eun Ha Kang, Eun Bong Lee, Churl Hyun Im, Jin Hyun Kim, Jeong Jin Park, Jung Chan Lee, Sung Hwan Kim, Yeong Wook Song. (2005) A Case of Femoral Compressive Neuropathy in AL Amyloidosis. Journal of Korean Medical Science 20:3, 524
CrossRef124
Claude Vital, Anne Vital, Sandrine Bouillot-Eimer, Christiane Brechenmacher, Xavier Ferrer, Alain Lagueny. (2004) Amyloid neuropathy: a retrospective study of 35 peripheral nerve biopsies. Journal of the Peripheral Nervous System 9:4, 232-241
CrossRef125
Simon W. Dubrey, Margaret M. Burke, Philip N. Hawkins, Nicholas R. Banner. (2004) Cardiac transplantation for amyloid heart disease: The United Kingdom experience. The Journal of Heart and Lung Transplantation 23:10, 1142-1153
CrossRef126
Arie J Stangou, Philip N Hawkins. (2004) Liver transplantation in transthyretin-related familial amyloid polyneuropathy. Current Opinion in Neurology 17:5, 615-620
CrossRef127
L. Novak. (2004) AL-amyloidosis is underdiagnosed in renal biopsies. Nephrology Dialysis Transplantation 19:12, 3050-3053
CrossRef128
Lee-Ching Zhu, Gurdip S Sidhu, Herman T Yee, Nicholas D Cassai, David S Goldfarb, Rosemary L Wieczorek. (2004) AA-type amyloidosis associated with non-Hodgkin’s lymphoma: A case report. Human Pathology 35:8, 1041-1044
CrossRef129
Morie A. Gertz. (2004) The Classification and Typing of Amyloid Deposits. American Journal of Clinical Pathology 121:6, 787-789
CrossRef130
(2004) Guidelines on the diagnosis and management of AL amyloidosis. British Journal of Haematology 125:6, 681-700
CrossRef131
Laura Obici, Giovanni Palladini, Sofia Giorgetti, Vittorio Bellotti, Gina Gregorini, Eloisa Arbustini, Laura Verga, Sabrina Marciano, Simona Donadei, Vittorio Perfetti, Laura Calabresi, Cesare Bergonzi, Francesco Scolari, Giampaolo Merlini. (2004) Liver biopsy discloses a new apolipoprotein A-I hereditary amyloidosis in several unrelated Italian families. Gastroenterology 126:5, 1416-1422
CrossRef132
Morie A Gertz, Martha Q Lacy, Angela Dispenzieri. (2004) Therapy for immunoglobulin light chain amyloidosis: the new and the old. Blood Reviews 18:1, 17-37
CrossRef133
Hannah R. Briemberg, Anthony A. Amato. (2004) Transthyretin amyloidosis presenting with multifocal demyelinating mononeuropathies. Muscle & Nerve 29:2, 318-322
CrossRef134
G Merlini, P Westermark. (2004) The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies. Journal of Internal Medicine 255:2, 159-178
CrossRef135
Gideon M Hirschfield. (2004) Amyloidosis: a clinico-pathophysiological synopsis. Seminars in Cell & Developmental Biology 15:1, 39-44
CrossRef136
Masahide Yazaki, Juris J Liepnieks, John Callaghan, Charles E Connolly, Merrill D Benson. (2004) Chemical characterization of a lambda I amyloid protein isolated from formalin-fixed and paraffin-embedded tissue sections. Amyloid 11:1, 50-55
CrossRef137
Marvin J. Stone, Michael J. Guirl. 2004. Amyloidosis. , 59-69.
CrossRef138
Mamede de Carvalho, Reinhold P Linke, Fernando Domingos, Teresinha Evangelista, José Luís Ducla-Soares, Walter BJ Nathrath, Conceição Azevedo-Coutinho, Raquel Lima, Maria João Saraiva. (2004) Mutant fibrinogen A-α-chain associated with hereditary renal amyloidosis and peripheral neuropathy. Amyloid 11:3, 200-207
CrossRef139
Shu-ichi IKEDA. (2004) Cardiac Amyloidosis: Heterogenous Pathogenic Backgrounds. Internal Medicine 43:12, 1107-1114
CrossRef140
Elizabeth B Haagsma, Philip N Hawkins, Merrill D Benson, Helen J Lachmann, Alison Bybee, Bouke PC Hazenberg. (2004) Familial amyloidotic polyneuropathy with severe renal involvement in association with transthyretin Gly47Glu in Dutch, British and American-Finnish families. Amyloid 11:1, 44-49
CrossRef141
Steve Vucic, Peter Siao Tick Chong, Didier Cros. (2003) Atypical presentations of primary amyloid neuropathy. Muscle & Nerve 28:6, 696-702
CrossRef142
G.M Hirschfield, P.N Hawkins. (2003) Amyloidosis: new strategies for treatment. The International Journal of Biochemistry & Cell Biology 35:12, 1608-1613
CrossRef143
Tisha Joy, Jian Wang, Angelika Hahn, Robert A. Hegele. (2003) Apoa1 related amyloidosis: a case report and literature review. Clinical Biochemistry 36:8, 641-645
CrossRef144
Merlini, Giampaolo, Bellotti, Vittorio, . (2003) Molecular Mechanisms of Amyloidosis. New England Journal of Medicine 349:6, 583-596
Full Text145
Sait Sen, Gulcin Basdemir. (2003) Diagnosis of renal amyloidosis using Congo red fluorescence. Pathology International 53:8, 534-538
CrossRef146
Helen J. Lachmann, Ruth Gallimore, Julian D. Gillmore, Hugh D. Carr-Smith, Arthur R. Bradwell, Mark B. Pepys, Philip N. Hawkins. (2003) Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. British Journal of Haematology 122:1, 78-84
CrossRef147
M. M. L. Hanss, P. O. Ffrench, J. F. Mornex, M. Chabuet, F. Biot, P. De Mazancourt, M. Dechavanne. (2003) Two novel fibrinogen variants found in patients with pulmonary embolism and their families. Journal of Thrombosis and Haemostasis 1:6, 1251-1257
CrossRef148
Philip N. Hawkins. (2002) Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis. Current Opinion in Nephrology and Hypertension 11:6, 649-655
CrossRef149
(2002) Hereditary Amyloidosis. New England Journal of Medicine 347:15, 1206-1207
Full Text150
Saraiva, Maria João Mascarenhas, . (2002) Sporadic Cases of Hereditary Systemic Amyloidosis. New England Journal of Medicine 346:23, 1818-1819
Full Text
- Letters
